Literature DB >> 10925230

Factors influencing early outcome of Norwood procedure for hypoplastic left heart syndrome.

E Malec1, K Januszewska, J Kołz, J Pajak.   

Abstract

OBJECTIVE: [corrected] The operative outcome of the Norwood procedure for hypoplastic left heart syndrome is still not satisfactory. Conflicting reports concern factors associated with early Norwood procedure mortality and the reasons for the instability after surgery are not sufficiently understood. The purpose of this study was to determine some perioperative factors influencing early (30 days) outcome.
METHODS: We retrospectively analyzed a group of 30 consecutive children with hypoplastic left heart syndrome (aged 5-39 days) who underwent Norwood procedure in 1997 and 1998. The following factors were considered and statistically analyzed: operative age, birth weight, operative weight, serum level of bilirubin, aminotransferases, creatinine, urea, arterial blood gasses, anatomic subgroups, ascending aorta and arch size, systemic to pulmonary modified right Blalock-Taussig shunt size, cardiopulmonary circulatory arrest time, cardiopulmonary bypass time, and delayed chest closure. Eighteen patients underwent hemi-Fontan procedure with one late death and the modified Fontan operation was performed in 16 of them (one late death).
RESULTS: The early mortality was 37%. Seven deaths (64%) occurred during the first 24 h after operation. There was a significant difference between survivals and non-survivals in: birth weight (P=0.047), operative age (P=0.016), preoperative serum level of bilirubin (P=0.044), and cardiopulmonary circulatory arrest time (P=0.006). The other assessed factors were not found to be predictors of early mortality. All 16 survivals followed up are in New York Heart Association class I or II.
CONCLUSIONS: Anatomic and functional status of the patient, as well as procedural factors are related to Norwood operation early mortality. High mortality in hypoplastic left heart syndrome after stage I surgery indicates the necessity of assessing all factors which may determine further improvement in the outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10925230     DOI: 10.1016/s1010-7940(00)00495-4

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Intensive care course after stage 1 Norwood procedure: are there early predictors of failure?

Authors:  Sylvie Di Filippo; Yichen Lai; Ana Manrique; Franck Pigula; Ricardo Muñoz
Journal:  Intensive Care Med       Date:  2006-11-18       Impact factor: 17.440

2.  Patient-specific parameter estimation in single-ventricle lumped circulation models under uncertainty.

Authors:  Daniele E Schiavazzi; Alessia Baretta; Giancarlo Pennati; Tain-Yen Hsia; Alison L Marsden
Journal:  Int J Numer Method Biomed Eng       Date:  2016-06-08       Impact factor: 2.747

3.  Staged surgical management of hypoplastic left heart syndrome: a single institution 12 year experience.

Authors:  S P McGuirk; M Griselli; O F Stumper; E M Rumball; P Miller; R Dhillon; J V de Giovanni; J G Wright; D J Barron; W J Brawn
Journal:  Heart       Date:  2005-06-06       Impact factor: 5.994

4.  Survival outcomes following norwood procedure for hypoplastic left heart.

Authors:  Jeffrey Shuhaiber; Brett Morgan; William Gottliebson
Journal:  Pediatr Cardiol       Date:  2014-07-31       Impact factor: 1.655

Review 5.  Left ventricle after palliation of hypoplastic left heart syndrome: friend, fiend, or innocent bystander?

Authors:  Jeffrey H Shuhaiber; Frank A Pigula
Journal:  Pediatr Cardiol       Date:  2013-03-22       Impact factor: 1.655

6.  Longitudinal Assessment of Outcome From Prenatal Diagnosis Through Fontan Operation for Over 500 Fetuses With Single Ventricle-Type Congenital Heart Disease: The Philadelphia Fetus-to-Fontan Cohort Study.

Authors:  Michael Y Liu; Benjamin Zielonka; Brian S Snarr; Xuemei Zhang; J William Gaynor; Jack Rychik
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.